ASSET OVERVIEW
A closer look at the opportunity.
Best-in-Class Potential Biparatopic ADC
Targets FRα+ tumors, overcoming resistance in low & medium expressors.
Biparatopic ADC Advantage
Dual-epitope binding enhances internalization and tumor targeting vs. conventional FRα ADCs.
Stronger Than ELAHERE (IMGN853)
Improved tumor cell binding, internalization, and broader efficacy across ovarian, endometrial, breast, and lung cancers.
Superior Payload & Stability
Potent TOPO-1 inhibitor, stable linker, and strong bystander effect for maximum impact.
Development Stage
IND-enabling studies; IND filing in November 2025.
Source: existing JEA asset materials. These descriptions include historical development plans and sponsor-reported data; contact JEA for current status and supporting materials.
← Back to all opportunities